RU2005111589A - Производные 1-пиридин-4-илмочевины - Google Patents
Производные 1-пиридин-4-илмочевины Download PDFInfo
- Publication number
- RU2005111589A RU2005111589A RU2005111589/04A RU2005111589A RU2005111589A RU 2005111589 A RU2005111589 A RU 2005111589A RU 2005111589/04 A RU2005111589/04 A RU 2005111589/04A RU 2005111589 A RU2005111589 A RU 2005111589A RU 2005111589 A RU2005111589 A RU 2005111589A
- Authority
- RU
- Russia
- Prior art keywords
- urea
- pyrrolidin
- general formula
- methylquinolin
- alkyl
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 29
- 125000003118 aryl group Chemical group 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 229910052757 nitrogen Inorganic materials 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 15
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 12
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 200000000007 Arterial disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 201000004569 Blindness Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 206010012335 Dependence Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010038419 Renal colic Diseases 0.000 claims 2
- 206010063897 Renal ischaemia Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 102000012327 Urotensin II receptors Human genes 0.000 claims 2
- 108050002984 Urotensin II receptors Proteins 0.000 claims 2
- -1 [1,8] naphthyridin-4-yl Chemical group 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 206010001902 amaurosis Diseases 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- 239000012050 conventional carrier Substances 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000007232 portal hypertension Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- CSJXSJKKACKVQN-UHFFFAOYSA-N 1-(1-benzylpyrrolidin-3-yl)-3-(2-methylquinolin-4-yl)urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1CC1=CC=CC=C1 CSJXSJKKACKVQN-UHFFFAOYSA-N 0.000 claims 1
- AVXTWBHRXGTMNK-XMMPIXPASA-N 1-(2,6-dimethylpyridin-4-yl)-3-[(3r)-1-(1,3-diphenylpropan-2-yl)pyrrolidin-3-yl]urea Chemical compound CC1=NC(C)=CC(NC(=O)N[C@H]2CN(CC2)C(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 AVXTWBHRXGTMNK-XMMPIXPASA-N 0.000 claims 1
- DAWSENUBSHJCQD-HSZRJFAPSA-N 1-(2,6-dimethylpyridin-4-yl)-3-[(3r)-1-(2-hydroxy-2,2-diphenylethyl)pyrrolidin-3-yl]urea Chemical compound CC1=NC(C)=CC(NC(=O)N[C@H]2CN(CC(O)(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 DAWSENUBSHJCQD-HSZRJFAPSA-N 0.000 claims 1
- ZTLMHQHOFUJVPJ-XMMPIXPASA-N 1-(2,6-dimethylpyridin-4-yl)-3-[(3r)-1-(3,3-diphenylpropyl)pyrrolidin-3-yl]urea Chemical compound CC1=NC(C)=CC(NC(=O)N[C@H]2CN(CCC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 ZTLMHQHOFUJVPJ-XMMPIXPASA-N 0.000 claims 1
- AVXTWBHRXGTMNK-DEOSSOPVSA-N 1-(2,6-dimethylpyridin-4-yl)-3-[(3s)-1-(1,3-diphenylpropan-2-yl)pyrrolidin-3-yl]urea Chemical compound CC1=NC(C)=CC(NC(=O)N[C@@H]2CN(CC2)C(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 AVXTWBHRXGTMNK-DEOSSOPVSA-N 0.000 claims 1
- CQQYYZAJXUOHTN-QHCPKHFHSA-N 1-(2,6-dimethylpyridin-4-yl)-3-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]urea Chemical compound CC1=NC(C)=CC(NC(=O)N[C@@H]2CN(CC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 CQQYYZAJXUOHTN-QHCPKHFHSA-N 0.000 claims 1
- DAWSENUBSHJCQD-QHCPKHFHSA-N 1-(2,6-dimethylpyridin-4-yl)-3-[(3s)-1-(2-hydroxy-2,2-diphenylethyl)pyrrolidin-3-yl]urea Chemical compound CC1=NC(C)=CC(NC(=O)N[C@@H]2CN(CC(O)(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 DAWSENUBSHJCQD-QHCPKHFHSA-N 0.000 claims 1
- ZTLMHQHOFUJVPJ-DEOSSOPVSA-N 1-(2,6-dimethylpyridin-4-yl)-3-[(3s)-1-(3,3-diphenylpropyl)pyrrolidin-3-yl]urea Chemical compound CC1=NC(C)=CC(NC(=O)N[C@@H]2CN(CCC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 ZTLMHQHOFUJVPJ-DEOSSOPVSA-N 0.000 claims 1
- VMIZAIMXAFAAJC-QHCPKHFHSA-N 1-(2-methylquinolin-4-yl)-3-[(3s)-1-[(2-phenylphenyl)methyl]pyrrolidin-3-yl]urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1CC1=CC=CC=C1C1=CC=CC=C1 VMIZAIMXAFAAJC-QHCPKHFHSA-N 0.000 claims 1
- DPDDVTVONRJHBM-UHFFFAOYSA-N 1-(2-methylquinolin-4-yl)-3-[1-(1-phenylethyl)pyrrolidin-3-yl]urea Chemical compound C1CC(NC(=O)NC=2C3=CC=CC=C3N=C(C)C=2)CN1C(C)C1=CC=CC=C1 DPDDVTVONRJHBM-UHFFFAOYSA-N 0.000 claims 1
- OBNSKGHLBBYGFD-UHFFFAOYSA-N 1-(2-methylquinolin-4-yl)-3-[1-(3-phenylpropyl)pyrrolidin-3-yl]urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1CCCC1=CC=CC=C1 OBNSKGHLBBYGFD-UHFFFAOYSA-N 0.000 claims 1
- UEXAKODCCRGVKK-UHFFFAOYSA-N 1-(2-methylquinolin-4-yl)-3-[1-(4-phenylcyclohexyl)pyrrolidin-3-yl]urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1C(CC1)CCC1C1=CC=CC=C1 UEXAKODCCRGVKK-UHFFFAOYSA-N 0.000 claims 1
- NSSFGHRLJFJRDV-UHFFFAOYSA-N 1-(2-methylquinolin-4-yl)-3-[1-(naphthalen-1-ylmethyl)pyrrolidin-3-yl]urea Chemical compound C1=CC=CC2=NC(C)=CC(NC(=O)NC3CN(CC=4C5=CC=CC=C5C=CC=4)CC3)=C21 NSSFGHRLJFJRDV-UHFFFAOYSA-N 0.000 claims 1
- XISUXQPUSTXGNA-UHFFFAOYSA-N 1-(2-methylquinolin-4-yl)-3-[1-(naphthalen-2-ylmethyl)pyrrolidin-3-yl]urea Chemical compound C1=CC=CC2=NC(C)=CC(NC(=O)NC3CN(CC=4C=C5C=CC=CC5=CC=4)CC3)=C21 XISUXQPUSTXGNA-UHFFFAOYSA-N 0.000 claims 1
- LZZUZEUKHIXPFM-UHFFFAOYSA-N 1-(2-methylquinolin-4-yl)-3-[1-[(3-phenylphenyl)methyl]pyrrolidin-3-yl]urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 LZZUZEUKHIXPFM-UHFFFAOYSA-N 0.000 claims 1
- NQNGYSXJFKNLEU-UHFFFAOYSA-N 1-(2-methylquinolin-4-yl)-3-[1-[(4-phenylphenyl)methyl]pyrrolidin-3-yl]urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1CC(C=C1)=CC=C1C1=CC=CC=C1 NQNGYSXJFKNLEU-UHFFFAOYSA-N 0.000 claims 1
- YAMBRNOLFOVLAX-UHFFFAOYSA-N 1-(2-methylquinolin-4-yl)-3-pyrrolidin-3-ylurea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC1CCNC1 YAMBRNOLFOVLAX-UHFFFAOYSA-N 0.000 claims 1
- HQKNRZGCWMSVKG-NRWPOFLRSA-N 1-[(3r)-1-(1,1-diphenylpropan-2-yl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@@H](CC1)NC(=O)NC=2C3=CC=CC=C3N=C(C)C=2)N1C(C)C(C=1C=CC=CC=1)C1=CC=CC=C1 HQKNRZGCWMSVKG-NRWPOFLRSA-N 0.000 claims 1
- ALXDTSKWSQIQBV-RUZDIDTESA-N 1-[(3r)-1-(1,3-diphenylpropan-2-yl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1C(CC=1C=CC=CC=1)CC1=CC=CC=C1 ALXDTSKWSQIQBV-RUZDIDTESA-N 0.000 claims 1
- SIEDSGWYFKYBTE-XMMPIXPASA-N 1-[(3r)-1-(2-hydroxy-2,2-diphenylethyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1CC(O)(C=1C=CC=CC=1)C1=CC=CC=C1 SIEDSGWYFKYBTE-XMMPIXPASA-N 0.000 claims 1
- UQOCWXTYTANLFQ-RUZDIDTESA-N 1-[(3r)-1-(3,3-diphenylpropyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1CCC(C=1C=CC=CC=1)C1=CC=CC=C1 UQOCWXTYTANLFQ-RUZDIDTESA-N 0.000 claims 1
- LYSDRQQEDWTEPV-AREMUKBSSA-N 1-[(3r)-1-(3-cyano-3,3-diphenylpropyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 LYSDRQQEDWTEPV-AREMUKBSSA-N 0.000 claims 1
- CSJXSJKKACKVQN-GOSISDBHSA-N 1-[(3r)-1-benzylpyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1CC1=CC=CC=C1 CSJXSJKKACKVQN-GOSISDBHSA-N 0.000 claims 1
- HQKNRZGCWMSVKG-TUXUZCGSSA-N 1-[(3s)-1-(1,1-diphenylpropan-2-yl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@H](CC1)NC(=O)NC=2C3=CC=CC=C3N=C(C)C=2)N1C(C)C(C=1C=CC=CC=1)C1=CC=CC=C1 HQKNRZGCWMSVKG-TUXUZCGSSA-N 0.000 claims 1
- VASZNWWWMQOFBM-VWLOTQADSA-N 1-[(3s)-1-(1,3-diphenylpropan-2-yl)pyrrolidin-3-yl]-3-(2-ethyl-6-methylpyridin-4-yl)urea Chemical compound CC1=NC(CC)=CC(NC(=O)N[C@@H]2CN(CC2)C(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 VASZNWWWMQOFBM-VWLOTQADSA-N 0.000 claims 1
- DHDWSFLSMAUIST-SANMLTNESA-N 1-[(3s)-1-(1,3-diphenylpropan-2-yl)pyrrolidin-3-yl]-3-(2-methyl-6-propylpyridin-4-yl)urea Chemical compound CC1=NC(CCC)=CC(NC(=O)N[C@@H]2CN(CC2)C(CC=2C=CC=CC=2)CC=2C=CC=CC=2)=C1 DHDWSFLSMAUIST-SANMLTNESA-N 0.000 claims 1
- ALXDTSKWSQIQBV-VWLOTQADSA-N 1-[(3s)-1-(1,3-diphenylpropan-2-yl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1C(CC=1C=CC=CC=1)CC1=CC=CC=C1 ALXDTSKWSQIQBV-VWLOTQADSA-N 0.000 claims 1
- CYWRXQDEQUAXFP-DEOSSOPVSA-N 1-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]-3-(2-ethyl-6-methylpyridin-4-yl)urea Chemical compound CC1=NC(CC)=CC(NC(=O)N[C@@H]2CN(CC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 CYWRXQDEQUAXFP-DEOSSOPVSA-N 0.000 claims 1
- GXPLWDIDYGQCKQ-VWLOTQADSA-N 1-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]-3-(2-methyl-6-propylpyridin-4-yl)urea Chemical compound CC1=NC(CCC)=CC(NC(=O)N[C@@H]2CN(CC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 GXPLWDIDYGQCKQ-VWLOTQADSA-N 0.000 claims 1
- HVEANDTZNLHJIQ-QFIPXVFZSA-N 1-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]-3-[2-(methylamino)pyridin-4-yl]urea Chemical compound C1=NC(NC)=CC(NC(=O)N[C@@H]2CN(CC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 HVEANDTZNLHJIQ-QFIPXVFZSA-N 0.000 claims 1
- IMDOYOHUOKYNCY-DEOSSOPVSA-N 1-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]-3-[2-(propylamino)pyridin-4-yl]urea Chemical compound C1=NC(NCCC)=CC(NC(=O)N[C@@H]2CN(CC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 IMDOYOHUOKYNCY-DEOSSOPVSA-N 0.000 claims 1
- WCXCZVCXNBWKOL-OQDGBJHPSA-N 1-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]-3-[2-[(e)-2-(4-fluorophenyl)ethenyl]-6-methylpyridin-4-yl]urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C(\C=C\C=3C=CC(F)=CC=3)C=2)C)CN1CC(C=1C=CC=CC=1)C1=CC=CC=C1 WCXCZVCXNBWKOL-OQDGBJHPSA-N 0.000 claims 1
- IXJGJLGZEGYBFK-PMERELPUSA-N 1-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]-3-[2-[2-(4-fluorophenyl)ethyl]-6-methylpyridin-4-yl]urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C(CCC=3C=CC(F)=CC=3)C=2)C)CN1CC(C=1C=CC=CC=1)C1=CC=CC=C1 IXJGJLGZEGYBFK-PMERELPUSA-N 0.000 claims 1
- VUTISFXPLPGWAS-PMERELPUSA-N 1-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]-3-[2-methyl-6-(2-phenylethyl)pyridin-4-yl]urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C(CCC=3C=CC=CC=3)C=2)C)CN1CC(C=1C=CC=CC=1)C1=CC=CC=C1 VUTISFXPLPGWAS-PMERELPUSA-N 0.000 claims 1
- SIEDSGWYFKYBTE-DEOSSOPVSA-N 1-[(3s)-1-(2-hydroxy-2,2-diphenylethyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1CC(O)(C=1C=CC=CC=1)C1=CC=CC=C1 SIEDSGWYFKYBTE-DEOSSOPVSA-N 0.000 claims 1
- DBMMTKKCTNZCIH-VWLOTQADSA-N 1-[(3s)-1-(3,3-diphenylpropyl)pyrrolidin-3-yl]-3-(2-ethyl-6-methylpyridin-4-yl)urea Chemical compound CC1=NC(CC)=CC(NC(=O)N[C@@H]2CN(CCC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 DBMMTKKCTNZCIH-VWLOTQADSA-N 0.000 claims 1
- WDIFRXXJMMXIHN-SANMLTNESA-N 1-[(3s)-1-(3,3-diphenylpropyl)pyrrolidin-3-yl]-3-(2-methyl-6-propylpyridin-4-yl)urea Chemical compound CC1=NC(CCC)=CC(NC(=O)N[C@@H]2CN(CCC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC2)=C1 WDIFRXXJMMXIHN-SANMLTNESA-N 0.000 claims 1
- UQOCWXTYTANLFQ-VWLOTQADSA-N 1-[(3s)-1-(3,3-diphenylpropyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1CCC(C=1C=CC=CC=1)C1=CC=CC=C1 UQOCWXTYTANLFQ-VWLOTQADSA-N 0.000 claims 1
- MKBMVELFWQNGRT-HKBQPEDESA-N 1-[(3s)-1-(3,3-diphenylpropyl)pyrrolidin-3-yl]-3-[2-methyl-6-(2-phenylethyl)pyridin-4-yl]urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C(CCC=3C=CC=CC=3)C=2)C)CN1CCC(C=1C=CC=CC=1)C1=CC=CC=C1 MKBMVELFWQNGRT-HKBQPEDESA-N 0.000 claims 1
- XKPYPTHZQZGEOJ-NSAACQBQSA-N 1-[(3s)-1-(3,3-diphenylpropyl)pyrrolidin-3-yl]-3-[2-methyl-6-[(e)-2-phenylethenyl]pyridin-4-yl]urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C(\C=C\C=3C=CC=CC=3)C=2)C)CN1CCC(C=1C=CC=CC=1)C1=CC=CC=C1 XKPYPTHZQZGEOJ-NSAACQBQSA-N 0.000 claims 1
- LYSDRQQEDWTEPV-SANMLTNESA-N 1-[(3s)-1-(3-cyano-3,3-diphenylpropyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 LYSDRQQEDWTEPV-SANMLTNESA-N 0.000 claims 1
- CSJXSJKKACKVQN-SFHVURJKSA-N 1-[(3s)-1-benzylpyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CN1CC1=CC=CC=C1 CSJXSJKKACKVQN-SFHVURJKSA-N 0.000 claims 1
- ALXDTSKWSQIQBV-UHFFFAOYSA-N 1-[1-(1,3-diphenylpropan-2-yl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1C(CC=1C=CC=CC=1)CC1=CC=CC=C1 ALXDTSKWSQIQBV-UHFFFAOYSA-N 0.000 claims 1
- DHHPOFYXYGSYAA-UHFFFAOYSA-N 1-[1-(2,2-diphenylethyl)piperidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCCN1CC(C=1C=CC=CC=1)C1=CC=CC=C1 DHHPOFYXYGSYAA-UHFFFAOYSA-N 0.000 claims 1
- CRTFHNZNUSVPFV-UHFFFAOYSA-N 1-[1-(2,2-diphenylethyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1CC(C=1C=CC=CC=1)C1=CC=CC=C1 CRTFHNZNUSVPFV-UHFFFAOYSA-N 0.000 claims 1
- UPDHQNHNDZQQCH-UHFFFAOYSA-N 1-[1-(2,3-diphenylpropyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1CC(C=1C=CC=CC=1)CC1=CC=CC=C1 UPDHQNHNDZQQCH-UHFFFAOYSA-N 0.000 claims 1
- SIEDSGWYFKYBTE-UHFFFAOYSA-N 1-[1-(2-hydroxy-2,2-diphenylethyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1CC(O)(C=1C=CC=CC=1)C1=CC=CC=C1 SIEDSGWYFKYBTE-UHFFFAOYSA-N 0.000 claims 1
- OIONWMOQLFYNGW-UHFFFAOYSA-N 1-[1-(3,3-diphenylpropyl)piperidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCCN1CCC(C=1C=CC=CC=1)C1=CC=CC=C1 OIONWMOQLFYNGW-UHFFFAOYSA-N 0.000 claims 1
- UQOCWXTYTANLFQ-UHFFFAOYSA-N 1-[1-(3,3-diphenylpropyl)pyrrolidin-3-yl]-3-(2-methylquinolin-4-yl)urea Chemical compound C=12C=CC=CC2=NC(C)=CC=1NC(=O)NC(C1)CCN1CCC(C=1C=CC=CC=1)C1=CC=CC=C1 UQOCWXTYTANLFQ-UHFFFAOYSA-N 0.000 claims 1
- RSDWXTZHJWMBLA-NDEPHWFRSA-N 1-[2-(benzylamino)pyridin-4-yl]-3-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(NCC=3C=CC=CC=3)N=CC=2)CN1CC(C=1C=CC=CC=1)C1=CC=CC=C1 RSDWXTZHJWMBLA-NDEPHWFRSA-N 0.000 claims 1
- CJEDMDDAFSHOSR-SANMLTNESA-N 1-[2-(cyclopentylamino)pyridin-4-yl]-3-[(3s)-1-(2,2-diphenylethyl)pyrrolidin-3-yl]urea Chemical compound C([C@@H](C1)NC(=O)NC=2C=C(NC3CCCC3)N=CC=2)CN1CC(C=1C=CC=CC=1)C1=CC=CC=C1 CJEDMDDAFSHOSR-SANMLTNESA-N 0.000 claims 1
- XVCGTFIEKHXNQA-AREMUKBSSA-N 1-[[(2r)-1-(1,3-diphenylpropan-2-yl)pyrrolidin-2-yl]methyl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@@H]1CNC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CCN1C(CC=1C=CC=CC=1)CC1=CC=CC=C1 XVCGTFIEKHXNQA-AREMUKBSSA-N 0.000 claims 1
- XVCGTFIEKHXNQA-SANMLTNESA-N 1-[[(2s)-1-(1,3-diphenylpropan-2-yl)pyrrolidin-2-yl]methyl]-3-(2-methylquinolin-4-yl)urea Chemical compound C([C@H]1CNC(=O)NC=2C=C(N=C3C=CC=CC3=2)C)CCN1C(CC=1C=CC=CC=1)CC1=CC=CC=C1 XVCGTFIEKHXNQA-SANMLTNESA-N 0.000 claims 1
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 241000766026 Coregonus nasus Species 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 208000035202 High altitude pulmonary edema Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 102000050488 Urotensin II Human genes 0.000 claims 1
- 108010018369 Urotensin II Proteins 0.000 claims 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 1
- 229940116211 Vasopressin antagonist Drugs 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000007675 cardiac surgery Methods 0.000 claims 1
- 230000004706 cardiovascular dysfunction Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 210000004907 gland Anatomy 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 230000000877 morphologic effect Effects 0.000 claims 1
- VNHJBOJBSIKZAK-GDLZYMKVSA-N n,n-diethyl-4-[(3r)-3-[(2-methylquinolin-4-yl)carbamoylamino]pyrrolidin-1-yl]-2,2-diphenylbutanamide Chemical compound C([C@@H](CC1)NC(=O)NC=2C3=CC=CC=C3N=C(C)C=2)N1CCC(C(=O)N(CC)CC)(C=1C=CC=CC=1)C1=CC=CC=C1 VNHJBOJBSIKZAK-GDLZYMKVSA-N 0.000 claims 1
- VNHJBOJBSIKZAK-LJAQVGFWSA-N n,n-diethyl-4-[(3s)-3-[(2-methylquinolin-4-yl)carbamoylamino]pyrrolidin-1-yl]-2,2-diphenylbutanamide Chemical compound C([C@H](CC1)NC(=O)NC=2C3=CC=CC=C3N=C(C)C=2)N1CCC(C(=O)N(CC)CC)(C=1C=CC=CC=1)C1=CC=CC=C1 VNHJBOJBSIKZAK-LJAQVGFWSA-N 0.000 claims 1
- JLXQENRQYHVBGC-HHHXNRCGSA-N n,n-dimethyl-4-[(3r)-3-[(2-methylquinolin-4-yl)carbamoylamino]pyrrolidin-1-yl]-2,2-diphenylbutanamide Chemical compound C([C@@H](CC1)NC(=O)NC=2C3=CC=CC=C3N=C(C)C=2)N1CCC(C(=O)N(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 JLXQENRQYHVBGC-HHHXNRCGSA-N 0.000 claims 1
- JLXQENRQYHVBGC-MHZLTWQESA-N n,n-dimethyl-4-[(3s)-3-[(2-methylquinolin-4-yl)carbamoylamino]pyrrolidin-1-yl]-2,2-diphenylbutanamide Chemical compound C([C@H](CC1)NC(=O)NC=2C3=CC=CC=C3N=C(C)C=2)N1CCC(C(=O)N(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 JLXQENRQYHVBGC-MHZLTWQESA-N 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000003614 peroxisome proliferator Substances 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 239000002904 solvent Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000006016 thyroid dysfunction Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- HFNHAPQMXICKCF-USJMABIRSA-N urotensin-ii Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O HFNHAPQMXICKCF-USJMABIRSA-N 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- 229960003726 vasopressin Drugs 0.000 claims 1
- 239000003038 vasopressin antagonist Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP02/10417 | 2002-09-17 | ||
| EP0210417 | 2002-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005111589A true RU2005111589A (ru) | 2006-01-20 |
Family
ID=32010909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005111589/04A RU2005111589A (ru) | 2002-09-17 | 2003-09-12 | Производные 1-пиридин-4-илмочевины |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20060094716A1 (enExample) |
| EP (1) | EP1554249A2 (enExample) |
| JP (1) | JP2006505533A (enExample) |
| KR (1) | KR20050043967A (enExample) |
| CN (1) | CN1681789A (enExample) |
| AU (1) | AU2003270186A1 (enExample) |
| BR (1) | BR0314353A (enExample) |
| CA (1) | CA2496624A1 (enExample) |
| MX (1) | MXPA05002839A (enExample) |
| NO (1) | NO20050932L (enExample) |
| RU (1) | RU2005111589A (enExample) |
| WO (1) | WO2004026836A2 (enExample) |
| ZA (1) | ZA200502009B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050024A2 (en) | 2002-11-27 | 2004-06-17 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| WO2004073634A2 (en) | 2003-02-20 | 2004-09-02 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| US7288538B2 (en) | 2003-02-20 | 2007-10-30 | Encysive Pharmaceuticals, Inc. | Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists |
| JP2006519258A (ja) | 2003-02-28 | 2006-08-24 | エンサイシブ・ファーマシューティカルズ・インコーポレイテッド | ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬 |
| US7320989B2 (en) | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| EP1603899B1 (en) | 2003-03-06 | 2009-08-26 | Glaxo Group Limited | Heterocyclic urea derivatives for the treatment of pain |
| US7514562B2 (en) | 2003-03-07 | 2009-04-07 | Glaxo Group Limited | Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain |
| GB0305426D0 (en) | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| WO2004089296A2 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| JP4851328B2 (ja) | 2003-09-26 | 2012-01-11 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピリジン誘導体 |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| AR051213A1 (es) * | 2004-10-12 | 2006-12-27 | Actelion Pharmaceuticals Ltd | 1-(2-(4-bencil-4-hidroxi-piperidin-1-il)-etil)-3-(2-metil-quinolin-4-il)-urea como una sal sulfato cristalina |
| WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| NZ566023A (en) | 2005-09-21 | 2010-02-26 | Pfizer Ltd | Carboxamide derivatives as muscarinic receptor antagonists |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| WO2008144268A1 (en) * | 2007-05-15 | 2008-11-27 | Boehringer Ingelheim International Gmbh | Urotensin ii receptor antagonists |
| AU2009254738B2 (en) * | 2008-06-03 | 2014-05-08 | Idorsia Pharmaceuticals Ltd | [4-(1-amino-ethyl) -cyclohexyl] -methyl-amine and [6-(1-amino-ethyl) -tetrahydro- pyran-3-yl] -methyl-amine derivatives as antibacterials |
| EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| EP2552893B1 (en) * | 2010-03-31 | 2014-10-29 | Actelion Pharmaceuticals Ltd. | Antibacterial isoquinolin-3-ylurea derivatives |
| CA2826034A1 (en) * | 2011-01-28 | 2012-08-02 | University Of Kentucky Research Foundation | Stilbene analogs and methods of treating cancer |
| EP3247692B1 (en) * | 2015-01-23 | 2022-09-07 | GVK Biosciences Private Limited | Inhibitors of trka kinase |
| CN107056673B (zh) * | 2016-09-09 | 2019-10-29 | 南京工业大学 | 一种3,4-二芳基马来酰亚胺衍生物及其制备方法与应用 |
| CN106432039B (zh) * | 2016-09-27 | 2019-02-22 | 南京工业大学 | 3,4-二芳基马来酰亚胺衍生物及其制备方法与应用 |
| WO2020042972A1 (zh) * | 2018-08-27 | 2020-03-05 | 北京赛特明强医药科技有限公司 | 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用 |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| KR20250168210A (ko) | 2023-02-16 | 2025-12-02 | 가셔브룸 바이오, 인크. | 헤테로시클릭 glp-1 효능제 |
| CN119219821A (zh) * | 2024-12-03 | 2024-12-31 | 江苏金杉新材料有限公司 | 用于湿法冶金的苯乙烯系阴离子树脂及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| AUPP003197A0 (en) * | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE60013250T2 (de) * | 1999-02-12 | 2005-09-08 | Smithkline Beecham P.L.C., Brentford | Phenylharnstoff- und Phenylthioharnstoffderivate als Orexinrezeptorantagonisten |
| JP2004529132A (ja) * | 2001-03-27 | 2004-09-24 | アクテリオン ファマシューティカルズ リミテッド | １，２，３，４−テトラヒドロイソキノリン誘導体 |
| CA2473892C (en) * | 2001-12-04 | 2010-09-21 | Actelion Pharmaceuticals Ltd | Novel quinoline derivatives |
-
2003
- 2003-09-12 KR KR1020057004455A patent/KR20050043967A/ko not_active Withdrawn
- 2003-09-12 RU RU2005111589/04A patent/RU2005111589A/ru not_active Application Discontinuation
- 2003-09-12 CN CNA038219646A patent/CN1681789A/zh active Pending
- 2003-09-12 BR BR0314353-8A patent/BR0314353A/pt not_active IP Right Cessation
- 2003-09-12 JP JP2004537065A patent/JP2006505533A/ja not_active Abandoned
- 2003-09-12 CA CA002496624A patent/CA2496624A1/en not_active Abandoned
- 2003-09-12 EP EP03750534A patent/EP1554249A2/en not_active Withdrawn
- 2003-09-12 AU AU2003270186A patent/AU2003270186A1/en not_active Abandoned
- 2003-09-12 WO PCT/EP2003/010154 patent/WO2004026836A2/en not_active Ceased
- 2003-09-12 US US10/528,043 patent/US20060094716A1/en not_active Abandoned
- 2003-09-12 MX MXPA05002839A patent/MXPA05002839A/es unknown
-
2005
- 2005-02-21 NO NO20050932A patent/NO20050932L/no not_active Application Discontinuation
- 2005-03-09 ZA ZA200502009A patent/ZA200502009B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004026836A8 (en) | 2005-05-12 |
| KR20050043967A (ko) | 2005-05-11 |
| BR0314353A (pt) | 2005-07-19 |
| CN1681789A (zh) | 2005-10-12 |
| NO20050932L (no) | 2005-04-15 |
| ZA200502009B (en) | 2005-11-01 |
| EP1554249A2 (en) | 2005-07-20 |
| WO2004026836A2 (en) | 2004-04-01 |
| CA2496624A1 (en) | 2004-04-01 |
| MXPA05002839A (es) | 2005-05-27 |
| WO2004026836A3 (en) | 2005-01-20 |
| US20060094716A1 (en) | 2006-05-04 |
| JP2006505533A (ja) | 2006-02-16 |
| AU2003270186A1 (en) | 2004-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006505533A5 (enExample) | ||
| KR100574109B1 (ko) | 헤테로고리형 티오에스테르 및 케톤 | |
| CN1331853C (zh) | 旋转异构酶活性的小分子抑制剂 | |
| US7153883B2 (en) | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds | |
| US6787555B2 (en) | Triazole compounds useful in treating diseases associated with unwanted cytokine activity | |
| US11001564B2 (en) | Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same | |
| CA2473892A1 (en) | Novel quinoline derivatives | |
| FR2814678A1 (fr) | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite | |
| EP2098231A1 (en) | Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury | |
| JP2002535323A5 (enExample) | ||
| CA2537127A1 (en) | Benzimidazolone compounds having 5-ht4 receptor agonistic activity | |
| RU2005102004A (ru) | Замещенные хинолины как антагонисты рецептора ccr5 | |
| MXPA05010816A (es) | Derivados de 4-(4- (heterociclilalcox}fenil)- 1-(heterociclil- carbonil) piperidina y compuestos relacionados como antagonistas de h3 de la histamina para el tratamiento de enfermedades neurologicas tales como alzheimer. | |
| RU2005114021A (ru) | Производные имидазола и их применение в качестве периферически-селективных ингибиторов дофамин-бета-гидролазы | |
| RU2007130532A (ru) | Дизамещенные мочевины в качестве ингибиторов киназы | |
| RU2011149635A (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаина | |
| HUP0001461A2 (hu) | Heterociklusos észterek, amidok, tioészterek és ketonok N-oxidjai | |
| US8802664B2 (en) | Benzazole derivatives as histamine H4 receptor ligands | |
| CA2475619A1 (en) | Piperidine derivatives | |
| ZA200102426B (en) | Drugs for improving vesical excretory strength. | |
| JP2011505388A (ja) | レニン阻害剤 | |
| CA2545092A1 (en) | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity | |
| RU2006113948A (ru) | Производные пиридина и их применение в качестве антагонистов уротензина ii | |
| JP2006525299A (ja) | アゼチジンカルボキサミド誘導体及びｃｂ１レセプター媒介障害の治療におけるその使用 | |
| JP2007506692A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20070924 |